1. Introduction
===============

Epilepsy is one of the most common chronic neurological disorders, and affects more than 50 million people worldwide.^\[[@R1]--[@R3]\]^ It has been reported that its prevalence was 6 to 8 per 1000 people, and its incidence was 26 to 40 per 100,000 people each year.^\[[@R4]\]^ The other study has also reported that about 10% people will suffer from at least 1 seizure in their lifetime.^\[[@R5]\]^ Of those, one third people will develop to epilepsy.^\[[@R5],[@R6]\]^

Many factors can cause epilepsy. However, stroke is one of the most common reasons for epilepsy in the elderly.^\[[@R7],[@R8]\]^ It is reported that 11.5% of patients with poststroke had a high risk of developing poststroke epilepsy (PSE) by 5 years, according to the Oxfordshire community stroke project.^\[[@R9]\]^

Regarding the treatment, antiepileptic drug (AED) therapy is reported to be effective in preventing recurrence and treatment in patients with epilepsy.^\[[@R10]--[@R12]\]^ However, if patients take long-term medications, serious adverse events (AEs) also accompanied with them.^\[[@R13],[@R14]\]^ Additionally, a minority of patients can be cured by the invasive resective epilepsy surgery. Thus, it is very important and necessary to find out an alternative therapy with few AEs to treat such disorder.

Invasive transcutaneous vagus nerve stimulation (TVNS) is a potential intriguing candidate.^\[[@R11]--[@R14]\]^ It has been reported that TVNS has been used to treat patients with epilepsy, and have achieved a promising effectiveness.^\[[@R15]--[@R17]\]^ However, no studies provide published data to support the TVNS therapy for treating PSE. In this study, we firstly evaluated the potential effects of TVNS therapy for the treatment in patients with PSE.

2. Methods and design
=====================

2.1. Design
-----------

This study was approved by the Ethical Committee of First Affiliated Hospital of Jiamusi University. It was conducted between January 2016 and May 2017 at First Affiliated Hospital of Jiamusi University. All patients provided written informed consent. Fifty-two patients with PSE were included in this study. They were equally divided into a treatment group, underwent TVNS therapy, and a control group, at waiting list. The outcomes were measured before and after treatment. The patients and investigators were not blinded because of the retrospective study. However, the analyst and outcome assessors were masked to the design of this study.

2.2. Patients
-------------

This study included 52 eligible patients with epilepsy aged from 22 to 73 years old. All patients were reported to experience more than 2 epilepsy attacks during the past 3 months with 2 episodes at least 24 hours intervals before the recruitment. Additionally, all patients underwent at least 1 antiepileptic drug before the study. The exclusion criteria applied to subjects who had brain tumors, abnormal functions of liver and kidney, history of drug or alcohol addiction, drug allergy history, history of epilepsy, status epilepticus, or epilepsy surgeries before the stroke, gestational or lactating women, and received TVNS therapy 1 month before the treatment.

2.3. Treatment
--------------

Twenty-seven patients in the treatment group received TVNS therapy at bilateral auricular concha by using TVNS device NEMOSR (cerbomed GmbH, Erlangen, Germany). It has 2 electrode clips, which placed at the ear vagus nerve. Each patient received TVNS, 30 minutes each session, 1 session daily, twice weekly for a total of 4 weeks. Twenty five patients in the control group were at waiting list during the treatment period.

2.4. Outcomes
-------------

The primary outcome was weekly seizure frequency. The secondary outcomes included seizure episode, and quality of life, measured by the Quality of Life in Epilepsy Inventory-31 (QOLIE-31).^\[[@R18]\]^ Additionally, AEs were also recorded duration the treatment period. All primary and secondary outcomes were measured and assessed before and after 4 weeks treatment.

2.5. Statistical analysis
-------------------------

All data were analyzed by a professional statistician using SPSS Statistics 17.0 (IBM Corp, Armonk, NY). Student *t* test was performed to analyze the continuous outcome data. Pearson *χ*^2^ or Fisher exact tests were applied to analyze the categorical outcome data. Statistical significance was defined as *P* \< .05.

3. Results
==========

The characteristics of all 52 included patients are listed in Table [1](#T1){ref-type="table"}. No significant differences were found regarding age, gender, epilepsy duration, stroke duration, weight, epilepsy types, and previous antiepileptic drugs used between 2 groups.

###### 

Characteristics of included patients at baseline.
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After treatment, patients in both groups did not show better outcomes in weekly seizure frequency (treatment group, *P* = .12; control group, *P* = .56; Table [2](#T2){ref-type="table"}), seizure episode (treatment group, *P* = .65; control group, *P* = .92; Table [3](#T3){ref-type="table"}), and QOLIE-31 (treatment group, *P* = .73; control group, *P* = .84; Table [4](#T4){ref-type="table"}), when compared with these outcomes before the treatment.

###### 

Comparison of weekly seizure frequency.
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###### 

Comparison of each seizure episode (min).
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###### 

Comparison of quality of life, measured by QOLIE-31.
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After treatment, patients in the treatment group also did not exert better effect in seizure frequency (*P* = .81; Table [2](#T2){ref-type="table"}), seizure episode (*P* = .75; Table [3](#T3){ref-type="table"}), and QOLIE-31 (*P* = .33; Table [4](#T4){ref-type="table"}), when compared with patients in the control group.

AEs related to the treatment are shown in Table [5](#T5){ref-type="table"}. All AEs are mild and acceptable. No severe AEs occurred during the treatment period, and no death related to the treatment was recorded.

###### 

Adverse events between 2 groups.
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4. Discussion
=============

To our best knowledge, this study first explored the effect of TVNS for PSE among Chinese stroke population. We applied TVNS therapy for treating PSE patients for a total of 4 weeks. Unfortunately, we did not find promising improvement in all outcome measurements.

Previous related study has reported to use TVNS just for treating epilepsy patients, but not the PSE subjects. It designed as a randomized controlled trial with TVNS treatment for a total of 20 weeks. It utilized both 1 Hz and 25 Hz TVNS stimulations for treating epilepsy patients.^\[[@R17]\]^ The results found that TVNS had a high treatment adherence and was well tolerated.^\[[@R17]\]^ In our study, we only applied 4 weeks and used 1 Hz TVNS stimulation.

The results this study did not show better outcomes neither in the reduction of weekly seizure frequency, and seizure episode, nor in the improvement of quality of life, measured by QOLIE-31 among Chinese PSE population. Such results presented may be due to the short treatment duration, and small number of sample size included in this study.

This study has following limitations: the treatment duration is relative short with only 4 weeks, which may affect the effect assessment of TVNS for PSE patients; the dose of this study may insufficient when compared with the previous study;^\[[@R17]\]^ the sample size in this study is also quite small; this study is a retrospective study, which may increase the risk of patient cases selection. Thus, further studies should avoid the above limitations to further investigate the effect of TVNS for the treatment in patients with PSE.

5. Conclusion
=============

The results of this study showed that TVNS may be not efficacious for the PSE after 4 weeks treatment.
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